Skip to content
MedsAcross

Medicine

Farxiga 5 mg tablet

Dapagliflozin propanediol · Oral · AstraZeneca Pharmaceuticals
Available on requestPrescription onlyUS FDA

Farxiga 5 mg tablet is a prescription medicine containing Dapagliflozin propanediol for oral use, marketed by AstraZeneca Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and…

Key facts

Active ingredient (INN)
Dapagliflozin propanediol
Brand
Farxiga
Strength
5 mg
Dosage form
Tablet
Route
Oral
Packs
30 tablets, 90 tablets, 50 pouches and 1 more
Marketing authorisation holder
AstraZeneca Pharmaceuticals
Manufacturers
AstraZeneca PharmaceuticalsA-S Medication SolutionsRemedyrepack
Origin register
US FDA, United States
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
14 January 2008
Identifiers
RxCUI 1486977, 1486981, 1488569 +1DailyMed set ID 01f90c94-71cb-4a1f-81ff-8004b850529b, 72ad22ae-efe6-4cd6-a302-98aaee423d69, ef9e9c8c-5460-4193-952a-0c249dd071bdNDC 50090-3482, 0310-6205, 70518-4614Application NDA202293

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
30 tablet, film coated in 1 bottle, plastic0310-6205-30AstraZeneca Pharmaceuticals2 February 2015
90 tablet, film coated in 1 bottle, plastic0310-6205-90AstraZeneca Pharmaceuticals18 March 2024
30 tablet, film coated in 1 bottle, plastic50090-3482-0A-S Medication Solutions15 June 2018
50 pouch in 1 box / 1 tablet, film coated in 1 pouch70518-4614-0Remedyrepack23 April 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Dapagliflozin propanediol 5 mg tablet.

Compare 1

Other strengths and forms of Dapagliflozin propanediol

Clinical summary

Dapagliflozin propanediol is a sodium-glucose cotransporter 2 inhibitor indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, among other approved uses. MedsAcross supplies Dapagliflozin propanediol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Dapagliflozin propanediol

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Farxiga 5 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.